Article Sidebar

PDF
Date Published: 19/06/2026
Abstract Views: 28
Views PDF: 11
DOI: https://doi.org/10.51298/vmj.v561i2.18313
Issue
Vol. 561 No. 2 (2026)
Section
Các bài báo
How to Cite
Nguyễn, N. T., Hoàng, G. H., Huỳnh, T. X. T., & Châu, V. T. (2026). ANXIETY PREVALENCE AND ITS RELATIONSHIP WITH EPIDEMIOLOGICAL AND CLINICAL FEATURES IN PSORIASIS PATIENTS AT HO CHI MINH CITY DERMATOLOGY HOSPITAL. Vietnam Medical Journal, 561(2). https://doi.org/10.51298/vmj.v561i2.18313

ANXIETY PREVALENCE AND ITS RELATIONSHIP WITH EPIDEMIOLOGICAL AND CLINICAL FEATURES IN PSORIASIS PATIENTS AT HO CHI MINH CITY DERMATOLOGY HOSPITAL

Ngọc Trai Nguyễn, Gia Huy Hoàng, Thị Xuân Tâm Huỳnh, Văn Trở Châu

Main Article Content

Abstract

Introduction: Psoriatic arthritis (PsA) is a chronic, progressive disease that significantly impairs patients’ quality of life. Objective: To assess the prevalence of anxiety disorders and analyze their association with epidemiological and clinical characteristics among psoriasis patients in Vietnam. Subjects and Methods: A cross-sectional study was conducted with a convenience sample of 215 psoriasis patients at Ho Chi Minh City Hospital of Dermato Venereology from April 2024 to August 2024. Patients were clinically diagnosed with psoriasis and assessed for anxiety using the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A). Results: The prevalence of anxiety was 34.0%, of which 21.9% mild anxiety, 11.6% moderate, and 0.5% have severity anxiety. Depression, BSA > 10%, and sleep disturbance were three independent risk factors associated with anxiety disorders. In addition, patients with long-standing psoriasis, treated with biologics, and treated continuously reported a lower risk of anxiety. Conclusion: Anxiety is present in 34.0% of psoriasis patients. Depression, large lesion area and sleep disorders, biologic treatment, duration of psoriasis and continuous treatment were factors associated with anxiety disorders in psoriasis patients.

Article Details

Keywords

Psoriasis, anxiety, HADS.

References

1. Boehncke W, Schön M. Disease burden and epidemiology. Lancet. 2015;386:983-994.
2. Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs. 2023;37(1):35-55.
3. Cai Q, Teeple A, Wu B, Muser E. Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis. J Med Econ. 2019;22(12):1290-1297.
4. Nguyen SH, Nguyen LH, Vu GT, et al. Health-related quality of life impairment among patients with different skin diseases in Vietnam: a cross-sectional study. Int J Environ Res Public Health. 2019;16(3):305.
5. Tee S, Lim Z, Theng C, Chan K, Giam Y. A prospective cross‐sectional study of anxiety and depression in patients with psoriasis in Singapore. Journal of the European Academy of Dermatology and Venereology. 2016;30(7):1159-1164.
6. Doğan Y, Kiliç FA, Özçelik S. Anxiety, depression, and sexual dysfunction in patients with psoriasis. Turkish Journal of Dermatology. 2022;16(2):62-69.
7. Jin W, Zhang S, Duan Y. Depression symptoms predict worse clinical response to etanercept treatment in psoriasis patients. Dermatology. 2018;235(1):55-64.
8. Yang Y, Koh D, Khoo L, Nyunt SZ, Ng V, Goh CL. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. International journal of dermatology. 2005;44(11):925-929.